Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Inerferon may cure BCCs
Injections of interferon directly into the lesion may provide cures for a large portion of patients with basal cell carcinoma (BCC), according to a report in the June issue of the Journal of the American Academy of Dermatology.
Injections of interferon directly into the lesion may provide cures for a large portion of patients with basal cell carcinoma (BCC), according to a report in the June issue of the Journal of the American Academy of Dermatology.
Researchers in Houston evaluated injection of interferon in 50 patients with a total of 98 BCCs, treated from 1985 to 1992. At an average follow-up of 13.5 years (10 years minimum), cures were achieved in 95 of the 98 lesions.
Related Videos
Related Content
